Skip to main content
Calidi Biotherapeutics, Inc. logo

Calidi Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · CLDI ISIN · US3207031010 US Manufacturing
Open in API
Filings indexed 374 across all filing types
Latest filing 2026-05-29 Capital/Financing Update
Country US United States of America
Listing US CLDI

About Calidi Biotherapeutics, Inc.

https://www.calidibio.com/

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company that develops targeted therapies for cancer. The company's proprietary technology platforms utilize allogeneic stem cells to deliver and shield oncolytic virus payloads from the patient's immune system. This approach is designed to enable the potentiation of the viral therapy, activating the immune system to destroy solid tumors and metastatic disease. Calidi's pipeline includes both systemic and localized treatments being investigated for various cancers, including a first-in-class, stem-cell-loaded viral therapy for soft tissue sarcoma which has received FDA Fast Track Designation.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 85% confidence The document is a Form 8-K current report filed with the SEC describing an unregistered private placement of equity securities (issuance of amended warrants convertible into common stock). This is a financing event and a capital structure change, matching the “Capital/Financing Update” category (Code: CAP).
2026-05-29 English
8-K
Regulatory Filings Classification · 65% confidence The document is a Current Report on Form 8-K filed with the SEC, notifying of a press release on quarterly financial results. It does not contain the full earnings text but is a regulatory filing itself. Under the taxonomy, Form 8-K filings fall into the fallback category for miscellaneous regulatory filings (RNS).
2026-05-14 English
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
Capital/Financing Update Classification · 80% confidence The document is a Form 8-K current report filed under the Securities Exchange Act of 1934. Item 1.01 and Item 3.02 describe the entry into a material definitive agreement and the unregistered sale of equity securities — specifically, the issuance of a warrant to purchase common stock in a private placement transaction. This constitutes a financing activity and a change in capital structure, rather than a dividend, management change, or proxy matter. According to our filing definitions, updates on company fundraising and capital structure changes fall under Capital/Financing Update (Code: CAP).
2026-05-08 English
10-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
Annual Report FY 2025
2026-03-27 English
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Calidi Biotherapeutics, Inc. It is a Current Report pursuant to the Securities Exchange Act of 1934, dated March 27, 2026. The key content includes Item 2.02 "Results of Operations and Financial Condition," which references a press release announcing financial results for the fourth quarter and full year ended December 31, 2025. The document states that the press release is furnished as Exhibit 99.1 and is not "filed" for certain regulatory purposes. The document itself does not contain detailed financial statements or substantive financial data but rather announces the issuance of a press release with financial results. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. The document is about the announcement of financial results, not a full report like an Annual Report (10-K) or Interim Report (IR). Therefore, the correct classification is Earnings Release (ER). The document length is just over 5,000 characters, and it contains the actual announcement text, not just a link or statement that a report is available, so it is not a Report Publication Announcement (RPA).
2026-03-27 English
8-K - CALIDI BIOTHERAPEUTICS, INC. (0001855485) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text specifically mentions "Item 7.01 Regulation FD Disclosure" and references an updated presentation made available on the company's website, furnished as Exhibit 99.1. The document does not contain detailed financial statements or comprehensive financial analysis but rather announces the availability of a presentation. The length of the document is 4374 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or furnishes a presentation without containing the full report itself should be classified as an Investor Presentation (IP).
2026-02-10 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.